This Randomized Controlled Trial was to clarity the clinical feasibility of 3D-HDRA results in guiding the drug use of interventional chemotherapy after primary liver cancer surgery.
Data of Patients who received 3D-HDRA after primary liver cancer radical reaction and received Transarterial Chemoembolization #will be collected #excluding incomplete data. The primary endpoint was the one-year disease-free survival(DFS) rate #Secondary endpoint was the adverse event.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
144
130 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
20 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
50 mg per square body surface area for a total of four transcatheter hepatic artery infusions per month.
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, China
RECRUITINGThe one-year DFS rate
The one-year DFS rate is defined as the percentage of participants who have not accrued disease at the time of 1 year
Time frame: From the start date of the Treatment until date of the time of 1 year
Adverse events
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0
Time frame: From the beginning of therapy until the date of death from any cause(max 24 months)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
50 mg per square body surface area was used for monthly transhepatic arterial infusions.
Oxaliplatin(130 mg per square body surface area), Leucovorin(400 mg per square body surface area), and fluorouracil(2800 mg per square body surface area) were used for monthly transhepatic arterial infusions.
Lobaplatin(50 mg per square body surface area) and Raltitrexed(3 mg per square body surface area) were used for monthly transhepatic arterial infusions.